ORBIMED ADVISORS LLC 4
4 · Enliven Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Enliven Therapeutics (ELVN) — OrbiMed Advisors (10% Owner) Sells Shares
What Happened
OrbiMed Advisors LLC (reported as a 10% owner via affiliated funds) sold a total of 281,408 Enliven Therapeutics (ELVN) shares in open-market transactions on June 15, 2026. The sales were reported as two transactions: 9,086 shares at $45.02 each ($409,052) and 272,322 shares at $45.02 each ($12,259,936), for a combined proceeds of $12,668,988. These were outright sales (transaction code S), not purchases or option exercises.
Key Details
- Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (filed promptly after the transactions).
- Prices and amounts: 9,086 shares @ $45.02 = $409,052; 272,322 shares @ $45.02 = $12,259,936; total = $12,668,988.
- Shares owned after transaction: Not specified in the excerpt of the filing provided.
- Footnotes: Securities were held of record by OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP. OrbiMed Advisors is the managing member with voting/investment power; named committee members (Carl L. Gordon, Sven H. Borho, W. Carter Neild) disclaim beneficial ownership of the funds’ shares. The filing disclaims beneficial ownership except to the extent of any pecuniary interest.
- Filing timeliness: No late-filing indication; the Form 4 was filed two days after the trade date.
Context
This is an institutional sale by a reporting 10% owner (via affiliated funds), not an individual company executive. Institutional disposals can reflect portfolio management or rebalancing and do not necessarily signal management’s view of the company. The report shows direct sales (S); there is no indication of option exercises, gifts, or 10b5-1 plans in the provided filing.
Insider Transaction Report
- Sale
Common Stock
[F1][F3]2026-06-15$45.02/sh−9,086$409,052→ 245,728 total(indirect: See Footnotes) - Sale
Common Stock
[F2][F3]2026-06-15$45.02/sh−272,322$12,259,936→ 7,388,902 total(indirect: See Footnotes)
Footnotes (3)
- [F1]These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by Genesis and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
- [F2]These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.
- [F3]This report on Form 4 is filed by OrbiMed Advisors, GP VII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons or Gupta is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.